inactivated rabies vaccine merieux hdcv inj. sol. (pwdr. + solv.) i.m. vial + pre-filled syr.
sanofi pasteur europe s.a. - rabies virus (inactivated) ; albumin human 50 mg - powder and solvent for solution for injection - rabies virus, inactivated - rabies, inactivated, whole virus
nobivac rabies inj. susp. i.m./s.c. vial
intervet international b.v. - rabies virus (inactivated) >= 2 iu/dose - suspension for injection - rabies virus, inactivated - rabies virus - cattle; dog; horse; cat; sheep
rabies vaccine cultural concentrated purified inactivated dried lyophilisate for solution for i/m injection
federal state budgetary scientific institution chumakov federal scientific center for research and development of immune-and-bio - specific antigen of rabies virus vnukovo-32 strain - lyophilisate for solution for i/m injection - 2.5iu/ml
rabies vaccine cultural concentrated purified inactivated dried lyophilisate and solvent for solution for i/m injection
federal state budgetary scientific institution "chumakov federal scientific center for research and development of immune-and-bi - specific antigen of rabies virus "vnukovo-32" strain - lyophilisate and solvent for solution for i/m injection - 2.5iu/ml
rabies vaccine cultural concentrated purified inactivated dried lyophilisate and solvent for solution for i/m injection
federal state autonomous scientific institution "chumakov federal scientific center for research and development of immune-and-biological products of russian academy of sciences"(institute of poliomyelitis) - specific antigen of rabies virus "vnukovo-32" strain - lyophilisate and solvent for solution for i/m injection - 2.5iu/ml
imogam rabies pasteurized human rabies immunoglobulin 150 iu/ml injection vial
sanofi-aventis australia pty ltd - rabies immunoglobulin, quantity: 150 iu/ml - injection - excipient ingredients: glycine; sodium chloride; water for injections - imogam rabies pasteurized is indicated in subjects who are thought to have been exposed to rabies virus, especially cases of major exposure, in accordance with w.h.o. recommendations as specified in the international product information.
kamrab
kamada ltd, israel - human-rabies immunoglobulin - solution for injection - human-rabies immunoglobulin 150 iu/ml - rabies immunoglobulin - rabies immunoglobulin - kamrab im is indicated for passive, transient post-exposure prevention of rabies infection when given immediately to individuals in cases of contact with rabid or possibly rabid animal.
ixiaro suspension for injection 0.5ml in pre-filled syringe
aenon pharmaceuticals sea pte. ltd. - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) - injection, suspension - 6 μg/0.5 ml - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) 6 μg/0.5 ml
nobivac dhp
intervet ireland limited - canine distemper virus, strain onderstepoort; canine adenovirus type 2 strain manhattan lpv3 (live); canine parvovirus strain 154 (live) - lyophilisate and solvent for suspension for injection - . - canine distemper virus + canine adenovirus + canine parvovirus - dogs - immunological - live vaccine
vaqta hepatitis a vaccine inactivated 50 units/1ml injection syringe
merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: aluminium; water for injections; borax; sodium chloride - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.